AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) on 19 may files to sell 3.07M shares of common stock for holders. AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) net profit margin is -79.30% and weekly performance is 3.15%. On last trading day company shares ended up $9.16. Analysts mean target price for the company is $16.72. AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) distance from 50-day simple moving average (SMA50) is -15.54%.
Vical Incorporated (NASDAQ:VICL) reported on 6 may Total revenue was $2.4 million, up 55.5% from the year-ago quarter. The increase in revenues was due to higher payments from Astellas Pharma Inc. (ALPMY) under an exclusive license agreement for the development of ASP0113. Revenues surpassed the Zacks Consensus Estimate of $2 million. Vical Incorporated (NASDAQ:VICL) shares advanced 3.36% in last trading session and ended the day on $1.23. VICL gross Margin is -22.10% and its return on assets is -36.60%.Vical Incorporated (NASDAQ:VICL) quarterly performance is -15.75%.
IsoRay, Inc. (NYSEMKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic cancer, on 16 may announced its financial results for the quarter and nine months ended March 31, 2014. The loss per share increase of 3¢ per share for the quarter and 5¢ per share for the nine month period are attributable to the non-cash derivative liability increase caused by the increase in our common stock price for the quarter. IsoRay, Inc. (NYSEMKT:ISR) shares moved up 6.60% in last trading session and was closed at $2.26, while trading in range of $2.10 – $2.37. IsoRay, Inc. (NYSEMKT:ISR) year to date (YTD) performance is 352.00%.
Pharmacyclics, Inc. (NASDAQ:PCYC) announced that Gregory R. Wade has joined the company as Executive Vice President of Business Development. In his position, Greg will further establish the Business Development department and lead all Business Development and Competitive Intelligence efforts. Pharmacyclics, Inc. (NASDAQ:PCYC) ended the last trading day at $87.62. Company weekly volatility is calculated as 4.81% and price to cash ratio as 9.53.Pharmacyclics, Inc. (NASDAQ:PCYC) showed a negative weekly performance of -10.61%.
Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced that Ryan Dunlap, Vice President and Chief Financial Officer, will present a corporate update at the Marcum MicroCap Conference. The presentation will take place on Thursday, May 29, 2014 at 10:00 a.m. ET at The Grand Hyatt Hotel in New York City. Galena Biopharma Inc. (NASDAQ:GALE) weekly performance is 5.99%. On last trading day company shares ended up $2.30. Analysts mean target price for the company is $6.67. Galena Biopharma Inc. (NASDAQ:GALE) distance from 50-day simple moving average (SMA50) is -3.61%.